Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Immunovant Inc IMVT

Healthcare Biotechnology

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IMVT)

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

GlobeNewswire September 25, 2023

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire September 20, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

GlobeNewswire August 10, 2023

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

GlobeNewswire May 22, 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

GlobeNewswire February 3, 2023

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

GlobeNewswire November 7, 2022

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

GlobeNewswire November 4, 2022

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

GlobeNewswire October 4, 2022

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

GlobeNewswire September 28, 2022

Immunovant to Present at Roivant Investor Day on September 28th

GlobeNewswire September 21, 2022

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

GlobeNewswire September 9, 2022

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

GlobeNewswire September 7, 2022

Immunovant Announces Two New Development Programs for Batoclimab

GlobeNewswire September 7, 2022

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

GlobeNewswire August 24, 2022

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

GlobeNewswire August 5, 2022

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

GlobeNewswire June 8, 2022

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

GlobeNewswire June 6, 2022

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

GlobeNewswire May 23, 2022

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

GlobeNewswire May 19, 2022

Immunovant to Present at LifeSci Partners' Immunology and Inflammation Symposium on May 10th

GlobeNewswire May 4, 2022